Previous 10 | Next 10 |
EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review PR Newswire If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside appr...
On May 20, the U.S. Food and Drug Administration (FDA) approved Sanofi (NASDAQ: SNY) and Regeneron 's (NASDAQ: REGN) Dupixent as a treatment for patients, aged 12 years and older, with eosinophilic esophagitis (EoE). What was the data that prompted the FDA to make Dupixe...
Intellia Therapeutics (NASDAQ:NTLA) and Regeneron Pharmaceuticals (REGN) said on Friday that their experimental in vivo gene editing candidate NTLA-2001 was found to have a lasting therapeutic effect over 12 months in transthyretin (ATTR) amyloidosis. The interim readout included follow-up da...
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose PR Newswire Serum TTR reductions wer...
Harris Associates’ 13F portfolio value increased from $64.23B to $75.90B this quarter. They increased Charter Communications, General Motors, Amazon.com, and Netflix while reducing Humana, Hilton Worldwide, and General Dynamics. The top three positions are Alphabet, Fiserv,...
Regeneron acquired the global rights to Libtayo from Sanofi. The deal also brings acceleration of repayments to Sanofi. This is a no-brainer deal that allows Regeneron full control of Libtayo and this should lead to increased pipeline investments. Libtayo is just a part of an ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Do You Have These 4 Biotech Stocks on Your Watchlist? Biotech stocks have been one of the focal points of the stock market over the past two years. For obvious reasons, people and investors alike are always on the lookout for new developments against the coronavirus. But even wi...
In spite of half of our FMP's four building blocks trading in distress-mode, the portfolio/investment strategy is working just fine. Although stocks are no longer expensive, the economy is looking so fragile, posing a great deal of risk for further decline. This year's lead invest...
So far in 2022, Regeneron Pharmaceuticals (NASDAQ: REGN) stock has fallen by 14%. It recently hit a new 52-week low and trades at an incredibly low earnings multiple. But the company won't be able to rely on revenue from its COVID-19 treatment to prop up its financials anymore, and ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...